qls-111
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 29, 2024 (NCT06016972)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
KCNJ1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06030193 | Phase 2 | May 9, 2024 | Qlaris Bio, Inc. |
| NCT06249152 | Phase 2 | Apr 21, 2024 | Qlaris Bio, Inc. |
| NCT06016972 | Phase 2 | Jan 29, 2024 | Qlaris Bio, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qlaris Bio, Inc. | For profit | 3 | 3 | 1 | 2024 |
1 organizations
Page 1 / 1